Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19

Tomas O. Jensen*, Greg A. Grandits, Mamta K. Jain, Thomas A. Murray, Birgit Grund, Kathryn Shaw-Saliba, Michael A. Matthay, Mahsa Abassi, Magdalena Ardelt, Jason V. Baker, Peter Chen, Robin L. Dewar, Anna L. Goodman, Timothy J. Hatlen, Helene C. Highbarger, Mark Holodniy, Perrine Lallemand, Sylvain Laverdure, Bradley G. Leshnower, David LooneyCharalampos D. Moschopoulos, Henry Mugerwa, Daniel D. Murray, Eleftherios Mylonakis, Stephanie Nagy-Agren, M. Tauseef Rehman, Adam Rupert, Randy A. Stevens, Stuart Turville, Amy Weintrob, Katherine Wick, Jens Lundgren, Emily R. Ko*, ACTIV-3/TICO Study Group , Henrik Nielsen (Medlem af forfattergruppering), Rikke Krog Thisted (Medlem af forfattergruppering), Kristine Toft Petersen (Medlem af forfattergruppering), Maria Ruwald Juhl (Medlem af forfattergruppering)


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

2 Downloads (Pure)


Background: Neutralizing monoclonal antibodies (nmAbs) failed to show clear benefit for hospitalized patients with coronavirus disease 2019 (COVID-19). Dynamics of virologic and immunologic biomarkers remain poorly understood.

Methods: Participants enrolled in the Therapeutics for Inpatients with COVID-19 trials were randomized to nmAb versus placebo. Longitudinal differences between treatment and placebo groups in levels of plasma nucleocapsid antigen (N-Ag), anti-nucleocapsid antibody, C-reactive protein, interleukin-6, and D-dimer at enrollment, day 1, 3, and 5 were estimated using linear mixed models. A 7-point pulmonary ordinal scale assessed at day 5 was compared using proportional odds models.

Results: Analysis included 2149 participants enrolled between August 2020 and September 2021. Treatment resulted in 20% lower levels of plasma N-Ag compared with placebo (95% confidence interval, 12%-27%; P < .001), and a steeper rate of decline through the first 5 days (P < .001). The treatment difference did not vary between subgroups, and no difference was observed in trajectories of other biomarkers or the day 5 pulmonary ordinal scale.

Conclusions: Our study suggests that nmAb has an antiviral effect assessed by plasma N-Ag among hospitalized patients with COVID-19, with no blunting of the endogenous anti-nucleocapsid antibody response. No effect on systemic inflammation or day 5 clinical status was observed.
TidsskriftThe Journal of Infectious Diseases
Udgave nummer3
Sider (fra-til)671-679
Antal sider9
StatusUdgivet - 14 mar. 2024

Bibliografisk note

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.


Dyk ned i forskningsemnerne om 'Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19'. Sammen danner de et unikt fingeraftryk.